- Home
- EQX vs IONS Comparison
EQX vs IONS Comparison
Compare EQX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | IONS |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 12.1B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | EQX | IONS |
|---|---|---|
| Price | $10.14 | $42.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $83.83 |
| AVG Volume (30 Days) | ★ 9.6M | 2.9M |
| Earning Date | 11-09-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $113.43 | N/A |
| Revenue Next Year | $28.69 | $48.18 |
| P/E Ratio | $137.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.49 | $42.08 |
| 52 Week High | $18.96 | $86.74 |
Technical Indicators
Market Signals| Indicator | EQX | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 39.67 |
| Support Level | $9.34 | $42.57 |
| Resistance Level | $10.49 | $46.33 |
| Average True Range (ATR) | 0.43 | 1.52 |
| MACD | -0.05 | 0.47 |
| Stochastic Oscillator | 9.63 | 22.83 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).